-
Bal Pharma receives nod for three-time booster dose of Coronil tablet
Bal Pharma has received the Drugs Controller General of India's (DCGI) approval for using Coronil tablet as a three-time booster dose for Covid-19.
-
Bal Pharma launches new manufacturing facility in Sikkim
Bal Pharma has launched a new manufacturing facility in Sikkim to produce a range of pharmaceutical products.
-
Bal Pharma receives order from UNICEF for supply of antibiotics
Bal Pharma has received an order from UNICEF for the supply of antibiotics to be used in the treatment of childhood diseases.
-
Bal Pharma partners with global healthcare company for distribution of Covid-19 vaccine
Bal Pharma has partnered with a global healthcare company for the distribution of its Covid-19 vaccine.
-
Bal Pharma Ltd. Q4FY23 results: Consolidated net profit up 17.1%
Bal Pharma Ltd. has reported a 17.1% increase in its consolidated net profit to Rs 41.09 crore for the quarter ended March 31, 2023, as compared to Rs 35.10 crore in the corresponding quarter of the previous fiscal year. The company's total income for the quarter under review stood at Rs 223.76 crore, up by 11.6% from Rs 200.47 crore in the same period last year.
-
Bal Pharma Ltd. enters into strategic partnership with US-based company
Bal Pharma Ltd. has announced that it has entered into a strategic partnership with a US-based company to develop and commercialize a new drug for the treatment of cancer. The partnership will leverage Bal Pharma's expertise in drug development and manufacturing with the US company's experience in clinical trials and commercialization.
-
Bal Pharma Ltd. receives USFDA approval for generic drug
Bal Pharma Ltd. has received approval from the US Food and Drug Administration (USFDA) for its generic version of a popular drug used to treat high blood pressure and heart failure. The approval marks a significant milestone for the company as it expands its presence in the US market.
-
Bal Pharma partners with Syngene International for Discovery Research
Bal Pharma Ltd., a leading global pharmaceutical company, has announced a strategic partnership with Syngene International Ltd., a leading provider of integrated research, development, and manufacturing services, to accelerate drug discovery and development.
-
Bal Pharma receives US FDA approval for generic version of Pradaxa
Bal Pharma Ltd. announced that it has received final approval from the United States Food and Drug Administration (US FDA) to market Dabigatran Etexilate Capsules, the generic version of Pradaxa.
-
Bal Pharma strengthens its respiratory portfolio with the acquisition of InvaGen Pharmaceuticals Inc.
Bal Pharma Ltd. has acquired InvaGen Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative respiratory therapies.
-
Bal Pharma Q3 net profit rises 15% to Rs 79.5 crore
Bal Pharma reported a 15% increase in consolidated net profit to Rs 79.5 crore for the third quarter ended December 2022, as against Rs 69.1 crore in the same period last year.
-
Bal Pharma receives tentative approval for generic Vascepa from USFDA
Bal Pharma has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic Vascepa.
-
Bal Pharma launches new manufacturing facility in India
Bal Pharma has inaugurated a new manufacturing facility in Visakhapatnam, India. The facility will produce a range of pharmaceutical products, including injectables, oral solids, and topical formulations.
